Shelf-Stable, Protein-Derived Postbiotic Clears FDA Safety Review for Digestive and Immune Health Formulations

Superbrewed Food has brought to market Thryvia, a protein-derived postbiotic ingredient positioned for digestive and immune health formulations across supplements, foods, beverages, and pet nutrition.¹

"Consumers understand digestive comfort and immune health, but brand owners need differentiated ingredients backed by science that also work in real-world products," commented Bryan Tracy, the company's co-founder and CEO.

Because the ingredient is non-viable, meaning it contains no living organisms, its function does not depend on maintaining bacterial viability through processing and storage, a distinction the company is reportedly positioning as a formulation advantage over live probiotic strains. Superbrewed Food also added microbiome industry veteran Michael Bush, formerly president and CEO of the probiotic ingredient company Ganeden, as co-chairman of its board to help guide the ingredient's commercial expansion.

What Is Thryvia, and How Was It Cleared for Use in Food?

Thryvia is made from heat-killed Clostridium tyrobutyricum strain ASM19, an anaerobic bacterium, rendering it shelf-stable at room temperature without the cold-chain or viability-maintenance requirements associated with live probiotics. The ingredient received a "no questions" response from the FDA on its generally recognized as safe, or GRAS, notification in February 2024, more than 2 years before this commercial launch.²

A GRAS "no questions" letter reflects the agency's assessment that the safety conclusion is adequately supported for the intended food use; it is not an evaluation of the ingredient's efficacy claims. The notice covers use as a protein source in foods and beverages at defined concentration ranges, a regulatory scope distinct from any structure-function claims the company markets separately for supplement applications.

What Evidence Supports Thryvia's Digestive and Immune Health Positioning?

The company describes a research program spanning preclinical, animal, and human studies. Third-party preclinical work reportedly found selective activation of pattern-recognition receptors, including toll-like receptor 2, toll-like receptor 5, and nucleotide-binding oligomerization domain-containing protein 2, immune-signaling proteins involved in detecting bacterial components.

Controlled animal research is described as providing translational evidence of intestinal and host-response activity, while a completed 4-week study¹ measured consumer-perceived changes in digestive comfort rather than a clinically validated endpoint. None of this research has been cited to a peer-reviewed publication in the company's materials, and additional human studies are described as still underway.

Why Are Formulators Considering Postbiotics as an Alternative to Live Probiotics?

Postbiotics, broadly defined by a 2021 expert consensus statement from the International Scientific Association for Probiotics and Prebiotics as preparations of inactivated microorganisms or their components that confer a health benefit, have drawn formulator interest partly because they sidestep the viability-loss problem that affects live probiotic strains during manufacturing, distribution, and storage.³

That same consensus statement notes that evidence for specific postbiotic preparations varies considerably by strain and study, meaning the category label itself does not indicate a particular ingredient has been clinically validated.

What Are the Open Questions About the Current Evidence Base?

The consumer perception study cited in the launch materials measured self-reported comfort rather than an objective clinical outcome, and neither its sample size nor its statistical methodology has been made public. The preclinical receptor-activation findings describe a proposed mechanism rather than a demonstrated clinical effect.

Manufacturers evaluating Thryvia for specific structure-function claims will need underlying study data and, ideally, peer-reviewed publication before treating the current evidence base as equivalent to a completed clinical substantiation package.

References

1. Superbrewed Food, Inc. Superbrewed Food launches Thryvia, the first shelf-stable protein-derived postbiotic for digestive and immune health formulations. PR Newswire. August 19, 2026. Accessed August 25, 2026. https://www.prnewswire.com/news-releases/superbrewed-food-launches-thryvia-the-first-shelf-stable-protein-derived-postbiotic-for-digestive-and-immune-health-formulations-302855271.html

2. US Food and Drug Administration. GRAS Notice GRN 1129: Heat-killed Clostridium tyrobutyricum strain ASM#19. Closed February 22, 2024. Accessed August 25, 2026. https://www.hfpappexternal.fda.gov/scripts/fdcc/index.cfm?id=1129&set=GRASNotices

3. Salminen S, Collado MC, Endo A, et al. The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics. Nat Rev Gastroenterol Hepatol. 2021;18(9):649-667. doi:10.1038/s41575-021-00440-6